APA (7th ed.) Citation

JC, T., H, L., LJ, Y., ZN, D., CL, H., BW, T., . . . T, L. (2023). Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: A systemic review and meta-analysis. Clinical and experimental medicine, 23(6), 2115. https://doi.org/10.1007/s10238-022-00938-6

Chicago Style (17th ed.) Citation

JC, Tian, et al. "Adverse Events of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systemic Review and Meta-analysis." Clinical and Experimental Medicine 23, no. 6 (2023): 2115. https://doi.org/10.1007/s10238-022-00938-6.

MLA (9th ed.) Citation

JC, Tian, et al. "Adverse Events of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systemic Review and Meta-analysis." Clinical and Experimental Medicine, vol. 23, no. 6, 2023, p. 2115, https://doi.org/10.1007/s10238-022-00938-6.